Patricia Cunnane, MD
Obstetrics & Gynecology · Clearwater, FLNPI 1184610230
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,151 and has fallen 60.8% since, to $451 in 2025.
Across 169 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$528
- AbbVie$496
- Mayne Pharma Commercial LLC$302
- Sumitomo Pharma America, Inc.$281
- Sage Therapeutics, LLC$186
- Millicent US Inc$149
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,20592%
- Education$2718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 17 | $528 |
| AbbVie(2 entities) | 29 | $496 |
| Mayne Pharma Commercial LLC | 11 | $302 |
| Sumitomo Pharma America, Inc. | 15 | $281 |
| Sage Therapeutics, LLC | 11 | $186 |
| Millicent US Inc | 7 | $149 |
| Exeltis, USA Inc. | 6 | $129 |
| Myovant Sciences Inc. | 6 | $124 |
| Agile Therapeutics, Inc. | 7 | $121 |
| Organon | 4 | $97 |
| Pfizer | 5 | $88 |
| Therapeuticsmd, Inc. | 6 | $80 |
| Myriad Women's Health, Inc. | 1 | $74 |
| Coopersurgical, Inc. | 4 | $70 |
| Meditrina | 4 | $66 |
| Bayer | 3 | $57 |
| Exact Sciences | 3 | $50 |
| AMAG Pharmaceuticals, Inc. | 4 | $49 |
| Mylan Pharmaceuticals Inc. | 3 | $45 |
| Duchesnay USA Incorporated | 2 | $44 |
| Novo Nordisk | 2 | $44 |
| Dysis Medical, Inc. | 1 | $42 |
| Amgen | 2 | $42 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Aspira Women's Health Inc | 1 | $34 |
| Evofem Biosciences, Inc. | 2 | $34 |
| Boston Scientific | 1 | $33 |
| Mimedx Group, Inc. | 1 | $27 |
| Avion Pharmaceuticals | 2 | $26 |
| Covidien LP | 1 | $22 |
| Merck | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Roche Diagnostics Corporation | 1 | $17 |
| Renovia Inc | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Convatec Inc. | 1 | $11 |
How this compares
$3,476 in reported general payments places this provider in the 80th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 11 | $5,772 |
| Estradiol | 63 | $1,439 |
| DottiEstradiol | 13 | $1,438 |
| Estradiol (Once Weekly)Estradiol | 14 | $678 |
| ProgesteroneProgesterone, Micronized | 20 | $648 |
| ValacyclovirValacyclovir Hcl | 27 | $594 |
| Fluconazole | 14 | $89 |
| Acyclovir | 16 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $528 | $5,77211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,438 obstetrics & gynecology providers in Florida.
Other obstetrics & gynecology in Clearwater
- Steven McCarusCelebration$2.3M
- Elliot CazesTampa$725K
- Charles BloomWinter Park$652K
- Jay CohenPlantation$556K
- Omar ZwainWinter Park$531K
- Keith AquaWellington$473K
- Jeffrey KotzenPalm Beach Gardens$413K
- Glenn BankertCrestview$388K
- Erica StockwellCelebration$321K
- Scott JordanFort Lauderdale$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.